Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon Nov 21, 2018 10:04am
51 Views
Post# 29004100

RE:RE:RE:Could be wrong but

RE:RE:RE:Could be wrong but
Quattro74 wrote: Fred, Toad, I think this is correct we will get some kind of financing deal in place with that 12 mth data. I'm betting it will be a jv with a cancan partner for GBM. Which will also provide us conditional monies for the nmibc phase 2. Without some type of funding deal I don't see an easy way for us to start, and finish, phase 2.


The funding deal will be another PP at the best price the company can manage. It's that simple. Whether 2 patients are enough to loosen the financial market's purse strings remains to be seen. It would help if they have a dynamic new CEO calling the shots to help sell the next $10 million PP. Confidence in management goes a long way to impress the smart money. I don't think the way this company is set up right now that they have the confidence of the market.
Bullboard Posts